Back to top
more

Avanos Medical (AVNS)

(Delayed Data from NYSE)

$19.56 USD

19.56
152,806

+0.02 (0.10%)

Updated May 8, 2024 04:00 PM ET

After-Market: $19.56 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Quest Diagnostics (DGX) Advances Access to Transplant Services

by Zacks Equity Research

Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.

Is Avanos Medical (AVNS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Avanos Medical (AVNS) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers

by Zacks Equity Research

In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.

National Vision (EYE) Rides on Comps Growth Amid Macro Issues

by Zacks Equity Research

National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.

3 Reasons to Add Avanos (AVNS) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Illumina (ILMN) to Expand Genomics Capacity With New Pact

by Zacks Equity Research

Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.

Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.

Illumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone

by Zacks Equity Research

Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.

3 Reasons to Retain Integer Holdings (ITGR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.

CVS Health's (CVS) New Initiatives Aid, Margin Woes Linger

by Zacks Equity Research

CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.

Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment

by Zacks Equity Research

Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.

Community Health (CYH) Divests Hospital for $92 Million

by Zacks Equity Research

Community Health (CYH) divests a healthcare facility in West Virginia, thereby reinforcing the sincere focus that it puts to shed non-core assets and use funds to grow well-performing business areas.

LabCorp (LH) Expands Colon Cancer Test Access With New Pact

by Zacks Equity Research

LabCorp's (LH) at-home collection kit will offer patients an additional and easier option to get screened for colon cancer.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.

3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Masimo's (MASI) New FDA Clearance to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) receipt of the FDA's De Novo grant is expected to combat opioid overdoses by boosting patient monitoring.

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Medtronic (MDT) Launches New Venture to Treat Kidney Failure

by Zacks Equity Research

Medtronic's (MDT) new venture is dedicated to reshaping kidney health and driving patient-centered technology solutions.

Tandem Diabetes (TNDM) Gains on Pump Sales, Margin Woe Stays

by Zacks Equity Research

Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.

Why You Should Add Hologic (HOLX) to Your Portfolio Now

by Zacks Equity Research

Hologic (HOLX) is currently well-positioned to achieve its full-year guidance of low double-digit organic growth ex-COVID in all three franchises, well above the 5-7% long-term growth rate.

Abbott's (ABT) Epic Max Tissue Valve Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) Epic Max design optimizes patient blood flow and has a low profile that makes future cardiac interventions simpler.

3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.

Neogen (NEOG) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Neogen (NEOG) delivers core growth in both the Food Safety and Animal Safety segments amid macroeconomic headwinds in the third quarter.

Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials

by Zacks Equity Research

Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.